Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.08.2012 | Epidemiology

Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution

verfasst von: E. Botteri, O. Gentilini, N. Rotmensz, P. Veronesi, S. Ratini, C. Fraga-Guedes, A. Toesca, C. Sangalli, A. Del Castillo, M. Rietjens, G. Viale, R. Orecchia, A. Goldhirsch, U. Veronesi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to identify the prognostic factors associated with the risk of loco-regional recurrence (LRR) of women undergoing mastectomy and complete axillary dissection without radiotherapy. We analyzed data from 650 women operated between 1997 and 2001 in a single institution. Median follow-up was 10 years. Overall survival was 89.8 % at 5 years and 76.6 % at 10 years. The 10-year cumulative incidence of LRRs was 10.0 % (5.0, 10.5, 15.8, and 18.5 % in patients with 0, 1–3, 4–9, and ≥10 positive lymph nodes (LNs), respectively). Sixty-two (9.5 %) LRRs were observed, 5 (0.8 %) of which occurred in the axillary LNs. Supraclavicular LNs recurrences (n = 16, 2.5 %) occurred more frequently in patients with four or more positive LNs, Ki-67 ≥ 20 % or extensive peritumoral vascular invasion (PVI). At multivariable analysis, nodal status was the only prognostic factor for local events, while nodal status, Ki-67 and PVI were significant prognostic factors for recurrences in the regional LNs. Moreover, within each category of positive LNs, high values of Ki-67 and extensive PVI were associated with the highest risk of LRR while low values of Ki-67 and absence of extensive PVI were associated with the lowest risk of LRR. Women with node-negative tumors have the lowest risk of LRR and represent the group of patients that might benefit the least from radiotherapy. PVI and Ki-67 might help tailoring PMRT indications among patients with positive LNs. Finally, the very low incidence of recurrences in the axillary LNs raises questions about the inclusion of the axilla in the radiation field.
Literatur
1.
Zurück zum Zitat Pierce LJ (2005) The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23(8):1706–1717PubMedCrossRef Pierce LJ (2005) The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23(8):1706–1717PubMedCrossRef
2.
Zurück zum Zitat National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 30:5–15 National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 30:5–15
3.
Zurück zum Zitat Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW Jr, Whelan TJ, Pfister DG (2001) American Society of Clinical Oncology. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(5):1539–1569PubMed Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW Jr, Whelan TJ, Pfister DG (2001) American Society of Clinical Oncology. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(5):1539–1569PubMed
4.
Zurück zum Zitat Sautter-Bihl ML, Souchon R, Budach W, Sedlmayer F, Feyer P, Harms W, Haase W, Dunst J, Wenz F, Sauer R (2008) DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol 184(7):347–353PubMedCrossRef Sautter-Bihl ML, Souchon R, Budach W, Sedlmayer F, Feyer P, Harms W, Haase W, Dunst J, Wenz F, Sauer R (2008) DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol 184(7):347–353PubMedCrossRef
5.
Zurück zum Zitat Killander F, Anderson H, Rydén S, Möller T, Aspegren K, Ceberg J, Danewid C, Malmström P (2007) Radiotherapy and tamoxifen after mastectomy in postmenopausal women: 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I. Eur J Cancer 43(14):2100–2108PubMedCrossRef Killander F, Anderson H, Rydén S, Möller T, Aspegren K, Ceberg J, Danewid C, Malmström P (2007) Radiotherapy and tamoxifen after mastectomy in postmenopausal women: 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I. Eur J Cancer 43(14):2100–2108PubMedCrossRef
6.
Zurück zum Zitat Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82(3):247–253PubMedCrossRef Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82(3):247–253PubMedCrossRef
7.
Zurück zum Zitat Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, Yu BL, Lee MY, Chi CW (2010) Radiotherapy can decrease loco-regional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys 77(2):516–522PubMedCrossRef Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, Yu BL, Lee MY, Chi CW (2010) Radiotherapy can decrease loco-regional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys 77(2):516–522PubMedCrossRef
8.
Zurück zum Zitat Macdonald SM, Abi-Raad RF, Alm El-Din MA, Niemierko A, Kobayashi W, McGrath JJ, Goldberg SI, Powell S, Smith B, Taghian AG (2009) Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys 75(5):1297–1303PubMedCrossRef Macdonald SM, Abi-Raad RF, Alm El-Din MA, Niemierko A, Kobayashi W, McGrath JJ, Goldberg SI, Powell S, Smith B, Taghian AG (2009) Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys 75(5):1297–1303PubMedCrossRef
9.
Zurück zum Zitat Abi-Raad R, Boutrus R, Wang R, Niemierko A, Macdonald S, Smith B, Taghian AG (2011) Patterns and risk factors of loco-regional recurrence in T1–T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 81(3):e151–e157PubMedCrossRef Abi-Raad R, Boutrus R, Wang R, Niemierko A, Macdonald S, Smith B, Taghian AG (2011) Patterns and risk factors of loco-regional recurrence in T1–T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 81(3):e151–e157PubMedCrossRef
10.
Zurück zum Zitat Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N (2006) Low loco-regional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 24(24):3927–3932PubMedCrossRef Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N (2006) Low loco-regional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 24(24):3927–3932PubMedCrossRef
11.
Zurück zum Zitat Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM (2010) Present-day loco-regional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899–2908PubMedCrossRef Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM (2010) Present-day loco-regional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899–2908PubMedCrossRef
12.
Zurück zum Zitat Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMed Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMed
13.
Zurück zum Zitat Gentilini O, Botteri E, Rotmensz N, Intra M, Gatti G, Silva L, Peradze N, Sahium RC, Gil LB, Luini A, Veronesi P, Galimberti V, Gandini S, Goldhirsh A, Veronesi U (2007) Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution. Ann Oncol 18(8):1342–1347PubMedCrossRef Gentilini O, Botteri E, Rotmensz N, Intra M, Gatti G, Silva L, Peradze N, Sahium RC, Gil LB, Luini A, Veronesi P, Galimberti V, Gandini S, Goldhirsh A, Veronesi U (2007) Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution. Ann Oncol 18(8):1342–1347PubMedCrossRef
14.
Zurück zum Zitat Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
15.
Zurück zum Zitat Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, International Breast Cancer Study Group Trials I through VII (2003) Risk factors for loco-regional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21(7):1205–1213PubMedCrossRef Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, International Breast Cancer Study Group Trials I through VII (2003) Risk factors for loco-regional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21(7):1205–1213PubMedCrossRef
16.
Zurück zum Zitat Berg JW (1955) The significance of axillary node levels in the study of breast carcinoma. Cancer 8(4):776–778PubMedCrossRef Berg JW (1955) The significance of axillary node levels in the study of breast carcinoma. Cancer 8(4):776–778PubMedCrossRef
17.
Zurück zum Zitat Cowen D, Gross E, Rouannet P, Teissier E, Ellis S, Resbeut M, Tallet A, Cowen VV, Azria D, Hannoun-Levi JM (2010) Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications. Breast Cancer Res Treat 121(3):627–634PubMedCrossRef Cowen D, Gross E, Rouannet P, Teissier E, Ellis S, Resbeut M, Tallet A, Cowen VV, Azria D, Hannoun-Levi JM (2010) Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications. Breast Cancer Res Treat 121(3):627–634PubMedCrossRef
Metadaten
Titel
Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution
verfasst von
E. Botteri
O. Gentilini
N. Rotmensz
P. Veronesi
S. Ratini
C. Fraga-Guedes
A. Toesca
C. Sangalli
A. Del Castillo
M. Rietjens
G. Viale
R. Orecchia
A. Goldhirsch
U. Veronesi
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2044-2

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.